{"id":350563,"date":"2026-11-17T15:09:46","date_gmt":"2026-11-17T09:39:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350563"},"modified":"2026-11-17T15:09:46","modified_gmt":"2026-11-17T09:39:46","slug":"tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/","title":{"rendered":"3 Tablets and Capsules Exporter, Multi-Speciality Hospitals Chain and Cloud IT Services Provider Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis: ROE of 11.6% to 20.5% and FY22 to FY26 revenue CAGR of 7.5% to 14.6%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>generic tablet, hospital and IT service stocks<\/strong> to watch are <strong>Lincoln Pharmaceuticals<\/strong>, <strong>Apollo Hospitals Enterprise<\/strong> and <strong>Mphasis<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>11.6% to 20.5%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.5% to 14.6%. Apollo Hospitals Enterprise leads on both return on equity at 20.5% and revenue growth at 14.6% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Generic tablet, hospital and IT service stocks offer a focused view of a sector where demand keeps widening. Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis cover a pharmaceuticals maker, a hospitals chain and an IT services company.<\/p>\n<p>This list covers three generic tablet, hospital and IT service stocks with complete current figures: Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#What_Are_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"What Are Generic Tablet, Hospital and IT Service Stocks?\">What Are Generic Tablet, Hospital and IT Service Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Generic_Tablet_Hospital_and_IT_Service_Stocks_at_a_Glance\" title=\"Generic Tablet, Hospital and IT Service Stocks at a Glance\">Generic Tablet, Hospital and IT Service Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Why_Do_Generic_Tablet_Hospital_and_IT_Service_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Generic Tablet, Hospital and IT Service Stocks Have a Strong Roadmap in India?\">Why Do Generic Tablet, Hospital and IT Service Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Why_Lincoln_Pharmaceuticals_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"Why Lincoln Pharmaceuticals Features Among These Generic Tablet, Hospital and IT Service Stocks\">Why Lincoln Pharmaceuticals Features Among These Generic Tablet, Hospital and IT Service Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Why_Apollo_Hospitals_Enterprise_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"Why Apollo Hospitals Enterprise Features Among These Generic Tablet, Hospital and IT Service Stocks\">Why Apollo Hospitals Enterprise Features Among These Generic Tablet, Hospital and IT Service Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Why_Mphasis_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"Why Mphasis Features Among These Generic Tablet, Hospital and IT Service Stocks\">Why Mphasis Features Among These Generic Tablet, Hospital and IT Service Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Lincoln_Pharmaceuticals_vs_Apollo_Hospitals_Enterprise_vs_Mphasis_on_Key_Financials\" title=\"Lincoln Pharmaceuticals vs Apollo Hospitals Enterprise vs Mphasis on Key Financials\">Lincoln Pharmaceuticals vs Apollo Hospitals Enterprise vs Mphasis on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Key_Risks_to_Check_Before_Investing_in_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"Key Risks to Check Before Investing in Generic Tablet, Hospital and IT Service Stocks\">Key Risks to Check Before Investing in Generic Tablet, Hospital and IT Service Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Final_Thoughts_on_Generic_Tablet_Hospital_and_IT_Service_Stocks\" title=\"Final Thoughts on Generic Tablet, Hospital and IT Service Stocks\">Final Thoughts on Generic Tablet, Hospital and IT Service Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#What_are_generic_tablet_hospital_and_IT_service_stocks\" title=\"What are generic tablet, hospital and IT service stocks?\">What are generic tablet, hospital and IT service stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Which_generic_tablet_hospital_and_IT_service_stocks_are_covered_in_this_list\" title=\"Which generic tablet, hospital and IT service stocks are covered in this list?\">Which generic tablet, hospital and IT service stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Why_do_generic_tablet_hospital_and_IT_service_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do generic tablet, hospital and IT service stocks have a strong future roadmap in India?\">Why do generic tablet, hospital and IT service stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#How_has_Lincoln_Pharmaceuticals_performed_financially\" title=\"How has Lincoln Pharmaceuticals performed financially?\">How has Lincoln Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#How_has_Apollo_Hospitals_Enterprise_performed_financially\" title=\"How has Apollo Hospitals Enterprise performed financially?\">How has Apollo Hospitals Enterprise performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#How_has_Mphasis_performed_financially\" title=\"How has Mphasis performed financially?\">How has Mphasis performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#What_risks_should_investors_check_before_buying_generic_tablet_hospital_and_IT_service_stocks\" title=\"What risks should investors check before buying generic tablet, hospital and IT service stocks?\">What risks should investors check before buying generic tablet, hospital and IT service stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it-services-provider-stocks-roadmap-tundra-list\/#Is_this_list_of_generic_tablet_hospital_and_IT_service_stocks_investment_advice\" title=\"Is this list of generic tablet, hospital and IT service stocks investment advice?\">Is this list of generic tablet, hospital and IT service stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>What Are Generic Tablet, Hospital and IT Service Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Generic tablet, hospital and IT service stocks<\/strong> are listed companies that make tablets, capsules and syrups for India and export markets, run large multi-speciality hospitals and a pharmacy network, and provide IT and cloud services to banks and other global clients. Their earnings depend on medicine orders, patient numbers and client technology budgets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Tablet_Hospital_and_IT_Service_Stocks_at_a_Glance\"><\/span><strong>Generic Tablet, Hospital and IT Service Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lincoln\/lincoln-pharmaceuticals-ltd-share-price-today\">Lincoln Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">521.15<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,067<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/apollohosp\/apollo-hospitals-enterprise-ltd-share-price-today\">Apollo Hospitals Enterprise<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,771<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">110,757<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">51.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mphasis\/mphasis-ltd-share-price-today\">Mphasis<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,432.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">47,695<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.24<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Lincoln Pharmaceuticals and Apollo Hospitals Enterprise trade at a <strong>P\/E<\/strong> below the industry P\/E, while Mphasis trades above it, which reflects the growth the market already expects. Readers comparing generic tablet, hospital and IT service stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic tablet, hospital and IT service stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Generic_Tablet_Hospital_and_IT_Service_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Generic Tablet, Hospital and IT Service Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Generic tablet, hospital and IT service stocks<\/strong> have a strong roadmap in India because steady demand for medicines, wider access to quality hospital care and rising client spending on cloud work keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pharmaceuticals.<\/strong> Patients need dependable medicines.<\/li>\n<li><strong>Hospitals.<\/strong> Families seek advanced care.<\/li>\n<li><strong>IT services.<\/strong> Clients move work to the cloud.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Lincoln_Pharmaceuticals_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>Why Lincoln Pharmaceuticals Features Among These Generic Tablet, Hospital and IT Service Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the generic tablet, hospital and IT service stocks on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.<\/p>\n<p>Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.<\/p>\n<p>In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a <strong>market capitalisation<\/strong> of Rs 1,067 crore. The stock trades at a <strong>P\/E<\/strong> of 11.1, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.<\/p>\n<p><strong>What to watch:<\/strong> Track branded product growth, export orders and new launches.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Apollo_Hospitals_Enterprise_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>Why Apollo Hospitals Enterprise Features Among These Generic Tablet, Hospital and IT Service Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma exporter, private hospitals and digital services shares on this list, Apollo Hospitals Enterprise is India&#8217;s largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%.<\/p>\n<p>Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.<\/p>\n<p><strong>What to watch:<\/strong> Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mphasis_Features_Among_These_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>Why Mphasis Features Among These Generic Tablet, Hospital and IT Service Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Mphasis is a Bengaluru-based IT services company that provides applications, cloud, data and consulting services to clients in banking, insurance and technology, especially in the United States.<\/p>\n<p>The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5.<\/p>\n<p>Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor deal wins and client spending trends in banking and financial services.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lincoln_Pharmaceuticals_vs_Apollo_Hospitals_Enterprise_vs_Mphasis_on_Key_Financials\"><\/span><strong>Lincoln Pharmaceuticals vs Apollo Hospitals Enterprise vs Mphasis on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three generic tablet, hospital and IT service stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Lincoln Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">482<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">704<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">87.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Apollo Hospitals Enterprise<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,741<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25,420<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,003<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mphasis<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,122<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,206<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,863<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise combines the largest FY26 revenue at Rs 25,420 crore with the fastest revenue growth, a 14.6% compound annual rate. A useful habit with <strong>generic tablet, hospital and IT service stocks<\/strong> is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several medicines, tertiary care and IT outsourcing stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Lincoln Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">169<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">202<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Apollo Hospitals Enterprise<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,882<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,092<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mphasis<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,813<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,467<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Generic Tablet, Hospital and IT Service Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these generic tablet, hospital and IT service stocks, the main points are: Long-term pharma exporter, private hospitals and digital services shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter generic tablet, hospital and IT service stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Generic_Tablet_Hospital_and_IT_Service_Stocks\"><\/span><strong>Final Thoughts on Generic Tablet, Hospital and IT Service Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Generic tablet, hospital and IT service stocks<\/strong> reward patient research into demand, execution and financial strength. Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis each have a clear plan to grow. Based on the 16 November 2026 close, Lincoln Pharmaceuticals trades at Rs 521.15, Apollo Hospitals Enterprise at Rs 8,771 and Mphasis at Rs 2,432.9. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these generic tablet, hospital and IT service stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track generic tablet, hospital and IT service stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_generic_tablet_hospital_and_IT_service_stocks\"><\/span><strong>What are generic tablet, hospital and IT service stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Generic tablet, hospital and IT service stocks are listed companies that make tablets, capsules and syrups for India and export markets, run large multi-speciality hospitals and a pharmacy network, and provide IT and cloud services to banks and other global clients. Their earnings depend on medicine orders, patient numbers and client technology budgets. This list looks at three of them, Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_generic_tablet_hospital_and_IT_service_stocks_are_covered_in_this_list\"><\/span><strong>Which generic tablet, hospital and IT service stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Based on the 16 November 2026 close, Lincoln Pharmaceuticals traded at Rs 521.15, Apollo Hospitals Enterprise at Rs 8,771 and Mphasis at Rs 2,432.9. Their return on equity ranges from <strong>11.6% to 20.5%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.5% to 14.6%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_generic_tablet_hospital_and_IT_service_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do generic tablet, hospital and IT service stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Generic tablet, hospital and IT service stocks<\/strong> have a strong roadmap in India because steady demand for medicines, wider access to quality hospital care and rising client spending on cloud work keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need dependable medicines. Hospitals. Families seek advanced care. IT services. Clients move work to the cloud. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Lincoln_Pharmaceuticals_performed_financially\"><\/span><strong>How has Lincoln Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P\/E of 11.1, below the industry P\/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Apollo_Hospitals_Enterprise_performed_financially\"><\/span><strong>How has Apollo Hospitals Enterprise performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mphasis_performed_financially\"><\/span><strong>How has Mphasis performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_generic_tablet_hospital_and_IT_service_stocks\"><\/span><strong>What risks should investors check before buying generic tablet, hospital and IT service stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying generic tablet, hospital and IT service stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_generic_tablet_hospital_and_IT_service_stocks_investment_advice\"><\/span><strong>Is this list of generic tablet, hospital and IT service stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are generic tablet, hospital and IT service stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Generic tablet, hospital and IT service stocks are listed companies that make tablets, capsules and syrups for India and export markets, run large multi-speciality hospitals and a pharmacy network, and provide IT and cloud services to banks and other global clients. Their earnings depend on medicine orders, patient numbers and client technology budgets. This list looks at three of them, Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which generic tablet, hospital and IT service stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Based on the 16 November 2026 close, Lincoln Pharmaceuticals traded at Rs 521.15, Apollo Hospitals Enterprise at Rs 8,771 and Mphasis at Rs 2,432.9. Their return on equity ranges from 11.6% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 14.6%.\"}},{\"@type\":\"Question\",\"name\":\"Why do generic tablet, hospital and IT service stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Generic tablet, hospital and IT service stocks have a strong roadmap in India because steady demand for medicines, wider access to quality hospital care and rising client spending on cloud work keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need dependable medicines. Hospitals. Families seek advanced care. IT services. Clients move work to the cloud. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Lincoln Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P\/E of 11.1, below the industry P\/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.\"}},{\"@type\":\"Question\",\"name\":\"How has Apollo Hospitals Enterprise performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P\/E of 51.0, below the industry P\/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.\"}},{\"@type\":\"Question\",\"name\":\"How has Mphasis performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying generic tablet, hospital and IT service stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying generic tablet, hospital and IT service stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of generic tablet, hospital and IT service stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Generic Tablet, Hospital and IT Service Stocks with a strong future roadmap: Lincoln Pharmaceuticals, Apollo Hospitals Enterprise and Mphasis. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":28,"featured_media":350562,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[14049,3803,25187,25188,11169,23488,7925,12356,25189,25190],"class_list":["post-350563","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-apollo-hospitals-enterprise","tag-best-stocks","tag-generic-tablet","tag-hospital-and-it-service-stocks","tag-lincoln-pharmaceuticals","tag-medicines","tag-mphasis","tag-pharma-exporter","tag-private-hospitals-and-digital-services-shares","tag-tertiary-care-and-it-outsourcing-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350562"],"rank_math_title":["Generic Tablet, Hospital Chain and IT Service Stocks"],"rank_math_description":["Compare 3 generic tablet, hospital and IT service stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["generic tablet, hospital and IT service stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-tablets-and-capsules-exporter-multi-speciality-hospitals-chain-and-cloud-it.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350563"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350563\/revisions"}],"predecessor-version":[{"id":350564,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350563\/revisions\/350564"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350562"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}